Ovarian Cancer Survivors
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC and Ashworth A. Nature. Vol. 434, p. 917-921, April 2005.
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis
Jennifer E. Quinn, Richard D. Kennedy, Paul B. Mullan, Paula M. Gilmore, Michael Carty, Patrick G. Johnston and D. Paul Harkin. Cancer
Research. Volume 63: p. 6221-6228, October 2003.
Improved
survival in women with BRCA-associated ovarian carcinoma
Ilana Cass, M.D., Rae Lynn Baldwin, Ph.D., Taz Varkey, M.D., Roxana Moslehi,
Ph.D., Steven A. Narod, M.D., Beth Y. Karlan, M.D.
Cancer. Volume 97, Issue 9: p. 2187-2195, April
2003.
Effect of BRCA
mutations on the length of survival in epithelial ovarian tumors
Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller,
G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, J. Menczer, B. Piura, J.P.
Struewing, B. Modan.
Journal of Clinical Oncology. Volume 20, Issue 2: p. 463-466, January,
2002.